Clinical Trials Browser

Phase 3 × INDUSTRY × peginterferon alfa-2a × Clear all

NCT02736721 2016-09-20

Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)

Phase 3 Completed

41 enrolled 8 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive